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Abstract
Purpose To describe the health-related quality of life
(HRQoL) of an unselected population of patients with
chronic lymphocytic leukaemia (CLL) including untreated
patients.
Methods HRQoL was measured by the EORTC QLQ-
C30 including the CLL16 module, EQ-5D, and VAS in an
observational study over multiple years. All HRQoL
measurements per patient were connected and analysed
using area under the curve analysis over the entire study
duration. The total patient group was compared with the
general population, and three groups of CLL patients were
described separately, i.e. patients without any active
treatment (‘‘watch and wait’’), chlorambucil treatment
only, and patients with other treatment(s).
Results HRQoL in the total group of CLL patients was
compromised when compared with age- and gender-mat-
ched norm scores of the general population. CLL patients
scored statistically worse on the VAS and utility score of
the EQ-5D, all functioning scales of the EORTC QLQ-
C30, and the symptoms of fatigue, dyspnoea, sleeping
disturbance, appetite loss, and financial difficulties. In
untreated patients, the HRQoL was slightly reduced. In all
treatment stages, HRQoL was compromised considerably.
Patients treated with chlorambucil only scored worse on
the EORTC QLQ-C30 than patients who were treated with
other treatments with regard to emotional functioning,
cognitive functioning, bruises, uncomfortable stomach, and
apathy.
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Conclusions CLL patients differ most from the general
population on role functioning, fatigue, concerns about
future health, and having not enough energy. Once treat-
ment is indicated, HRQoL becomes considerably com-
promised. This applies to all treatments, including
chlorambucil, which is considered to be a mild treatment.
Keywords Leukaemia  Lymphocytic  Chronic  B cell 
Quality of life  Area under curve  Observational study
Introduction
Chronic lymphocytic leukaemia (CLL) is the most com-
mon type of leukaemia occurring in the Western world,
affecting around 3–6 people per 100,000 persons [1–3].
Early symptoms of CLL are minimal and diagnosis often
follows the incidental finding of a high lymphocyte blood
count or lymph node swelling. Unlike most types of cancer,
the majority of CLL patients will not be treated immedi-
ately after diagnosis but will be monitored through a
‘‘watch and wait’’ approach [4]. Only upon disease pro-
gression and/or the development of CLL-related symptoms
such as fatigue, weight loss, malaise, bleeding, and recur-
rent or persistent infections [5, 6], treatment is indicated.
Disease-related symptoms, toxic effects of therapy, and
the awareness of living with an incurable disease [7] can
have a profound impact on health-related quality of life
(HRQoL). Despite these effects, little is known about the
HRQoL of patients living with CLL [7–9]. Currently,
nearly all available information is obtained during clinical
trials which also studied the influence of treatment with
chemotherapy on HRQoL [10–13]. However, the general-
isability of these studies is limited because these studies
only enrol patients in need of treatment. In addition, they
use strict inclusion and strict exclusion criteria, e.g. often
excluding patients over the age of 65.
The measurement of HRQoL in clinical trials which
enrol mostly younger patients in need of treatment is
valuable for comparison of treatments with regard to their
effect on HRQoL and the course of these effects over time,
i.e. from the start of treatment till the start of next treat-
ment. From the available studies, we know that the HRQoL
of patients during and after treatment with fludarabine plus
cyclophosphamide (FC) does not differ from that of
patients treated with fludarabine monotherapy on global
health score, physical and emotional functioning, and
fatigue. Patients treated with FC score worse on nausea and
vomiting during treatment, and better (but not significantly
better) after treatment than patients treated with fludarabine
monotherapy [11, 12]. However, these clinical trials do not
allow a conclusion with regard to the HRQoL in patients
who are not in need of treatment yet.
That information would be valuable since one-third of
all CLL patients [14] will not progress to treatment even
over decades. Current study provides an indication of the
type of symptoms that treatment-naı¨ve patients experience
and the limitations in daily functioning that occur. The
comparison of the HRQoL in untreated patients versus
those who just started treatment might give some indication
of the impact of starting first-line treatment on HRQoL.
When the HRQoL of untreated patients is already severely
compromised, the impact of expected side effects during
treatment on HRQoL is not likely to have a decisive role in
the decision whether to start treatment. In the opposite
situation, the expected impact of starting treatment on
HRQoL should be seriously considered in the decision
whether to start treatment or not.
None of the available studies that address HRQoL in the
whole CLL population [15–17] measured the HRQoL over
a period longer than 1 year. In order to fill this gap, we
conducted a longitudinal, multicentre observational study
including a HRQoL study.
Patients and methods
Inclusion and exclusion criteria
Nineteen hospitals in the Netherlands invited patients with
CLL for participation in an observational study addressing
the management of CLL, costs, and HRQoL [18]. Patients
aged 18 years or older diagnosed with CLL could enter the
study if he or she did not suffer from another serious
malignant disease or previous malignancy, had a complete
record, and gave informed consent. Patients who developed
a non-CLL-related malignancy were censored at the time
of its diagnosis.
Quality of life
Patients who participated in the HRQoL study received a
HRQoL questionnaire at the start, halfway through, and at
the end of therapy from their treating specialists. Addi-
tional questionnaires were sent every 6 months in the
periods without treatment to get information about the
HRQoL in the period before treatment and between treat-
ments. Since chlorambucil was frequently administered
continuously for a long and not predetermined period of
time, we choose to send questionnaires during this treat-
ment every 6 months as well, to get more information
about the HRQoL during the whole period of treatment.
The instruments employed in the HRQoL assessment
were the European Organisation for Research and Treat-
ment of Cancer (EORTC) QLQ-C30 accompanying CLL-
specific module [19] and a modified version of the EQ-5D
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in which five response levels replaced the original three
levels [20] as suggested and investigated by Kind and
Macran [21].
EORTC QLQ-C30
The EORTC QLQ-C30 has been developed by the EORTC
Quality of Life Study Group to assess the QoL of patients
with cancer [19]. The core instrument includes 30 ques-
tions covering many QoL issues related to cancer patients
in general and can be supplemented by a diagnosis-specific
module [22].
The questionnaire EORTC QLQ-C30 incorporates five
functional scales, three symptom scales, a global quality of
life scale (two items), and six single items. The functional
scales are physical functioning, role functioning, emotional
functioning, cognitive functioning, and social functioning.
The symptom scales are fatigue, nausea and vomiting, and
pain. Dyspnoea (shortness of breath), sleeping (distur-
bance), appetite loss, constipation, diarrhoea, and financial
difficulties are the six single items. According to the
EORTC scoring manual, scores were linearly transformed
to a 0–100 scale [23]. A higher score on the functional
scales and global quality of life scales meant better func-
tioning and quality of life, whereas a higher score on the
symptom scales meant more complaints. Differences in
scale scores of 10 points or more were considered clinically
meaningful [24].
In this study, the core questionnaire EORTC QLQ-C30
was supplemented by the CLL-specific module [25]. The
module is used to describe aspects of CLL that are not
included in the core questionnaire and provides informa-
tion about several domains. There are three multi-item
scales, i.e. fatigue, treatment side effects and disease
symptoms, infections, and two single item scales on social
activities and future health worries. However the module is
not yet officially published, the score on the scales cannot
be calculated [25], and the average score—ranging from 1
(not at all) to 4 (very much)—on the items can be
described.
Modified version of the EQ-5D
The EQ-5D measures the general HRQoL and is therefore
not influenced by CLL only. At the time of start of the
study, a five-level EQ-5D had been developed since the
original three-level EQ-5D was not sensitive enough for
smaller changes in HRQoL. Since patients with CLL in
general experience a high level of HRQoL [15], at least
until they reach the advanced stages, it was hypothesised
that this expanded five-level classification might provide a
more sensitive measure of change in health status than the
original three-level EQ-5D (EQ-5D3).
The modified version of the EQ-5D (EQ-5D5) [21]
comprised the same two items as the EQ-5D3: a visual
analogue scale (VAS) providing a single overall summary
score of HRQoL and descriptive classification with five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression). However, the descriptive
classification of the EQ-5D5 contained five levels, rather
than the standard three levels. The two additional levels
were unlabelled [21]. It can be seen as the predecessor of
the labelled five-level version of the EQ-5D [26], which did
not exist at the start of our study yet.
The responses on the descriptive classification can be
translated to a utility score, which is a value that reflects an
individual’s preference for a certain health outcome with
zero reflecting states of health equivalent to death and one
reflecting perfect health. Utility values for the EQ-5D5
states have never been determined, as this instrument has
been replaced by a five-level labelled version. We calcu-
lated utility values following the suggestion of the creator
of the EQ-5D5 [21]. The known utility values for the levels
1, 2, and 3 of the EQ-5D3 were used for the levels 1, 3, and
5 of the EQ-5D5, and the additional two levels were gen-
erated assuming the midpoint value between the standard
two tariff values using an adaptation of the Dutch three-
level tariff [27].
Statistical analysis
The HRQoL of a CLL patient over time was calculated by
connecting all measurements per patient using area under
the curve analysis over the entire study duration. To enable
the comparison of patients, we presented area under the
curve values corrected for the follow-up duration per
patient. For each patient, an individual norm score was
derived from age- and gender-matched scores of the gen-
eral population on the EQ-5D [28] and EORTC QLQ-C30
[29]. These two studies, as reported in Refs. [28] and [29],
used a panel consisting of more than 2000 Dutch house-
holds, representative of the Dutch-speaking non-institu-
tionalised population in the Netherlands.
Patient scores were compared with norm scores using
t test or nonparametric test for related samples (significant
when p\ 0.05). Patient scores of three patient groups
(patients without any active treatment, patients treated with
chlorambucil only, and other patients) were compared
using the Kruskal–Wallis test.
Subsequently, we chose to focus on the HRQoL during
two treatment phases. First, we focused on the question-
naires completed during the watch and wait phase since
data on this subject are scarce, and second on the ques-
tionnaires filled in during chlorambucil treatment because
this was the most frequently administered treatment in our
study. The results of both phases were described in a
Qual Life Res (2015) 24:2895–2906 2897
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separate section and compared using Kruskal–Wallis test
or t test depending on the variable distribution.
Results
Patient characteristics
Informed consent for participation was given by 173 CLL
patients. Of these, 13 patients (6 %) were excluded from
the analysis for the following reasons: eight patients did not
meet the inclusion criteria after all; one patient chart was
missing; and one patient withdrew himself from the study.
Additionally, one hospital dropped out of the study, leaving
three patients with incomplete follow-up data.
Of the 160 evaluable patients, 144 patients (90 %) par-
ticipated in the HRQoL study. Table 1 presents patient
characteristics of these 144 patients as a whole and per
patient group: patients who did not receive any active
treatment during the study period, patients who only
received chlorambucil, and patients with other or more
treatments. It also presents the characteristics of the patients
who did not participate in the HRQoL part of the study.
The mean age at diagnosis of all patients was 62.6 years
(SD = 10.5) of whom the majority were male (63 %). On
average, male patients were younger at diagnosis
(60.8 years, SD = 10.1) than female patients (65.5 year,
SD = 10.5). Age at diagnosis did not differ significantly
between the patient groups.
From diagnosis until the end of the HRQoL study, 85
patients received active treatment (59 %). Seventy-three
patients started treatment before the start of the HRQoL
study and 12 patients started their first-line treatment dur-
ing the study period. Eighty-five per cent of all patients
who received active treatment, were treated initially with
chlorambucil with or without prednisone. Other initial
treatments were chlorambucil–vincristine–prednisone
(CVP) (7 %), fludarabine (2 %), fludarabine–cyclophos-
phamide (FC, 2 %), rituximab plus CVP (R-CVP, 1 %),
cyclophosphamide (1 %), and cyclophosphamide–doxoru-
bicin–teniposide–prednisone with bleomycin–vin-
cristine ? radiotherapy (1 %). Fifty-three patients also
received subsequent line(s) of treatment. Second line
treatment was fludarabine monotherapy in most patients
(23 patients, 43 %). Other second line treatments were:
CVP (17 %), FC (8 %), FCR (8 %), R-CVP (8 %), chlo-
rambucil plus prednisone (6 %), rituximab (4 %), R-CHOP
(4 %), CVPP (2 %) and fludarabine–rituximab (FR, 2 %).
Patients were diagnosed for on average 3.9 years at the
time of their first questionnaire. Their last questionnaire
was on average completed 2.6 years later, at 6.5 years
since diagnosis. The mean number of questionnaires was
Table 1 Patient characteristics
All
participants
(n = 144)
Patients without any
active treatment
(n = 59)
Patients treated
with CLB only
(n = 28)
Other
patients
(n = 57)
Non-participants in
HRQoL study
(n = 16)
Age at diagnosis
Mean (SD) 62.6 (10.5) 64.1 (9.3) 63.6 (12.1) 60.5 (10.6) 71.0 (8.6)
Median 63 64 66 61 69
Range 30–86 34–82 30–86 38–85 56–84
Gender (% male) 62.5 59.3 50.0 71.9 62.5
Patients (%) with first- or second-degree
relatives with leukaemia or lymphoma
9.0 6.8 10.7 10.5 0.0
Binet Stage (%)
A 70.8 94.9 67.9 47.4 81.2
A progressive 2.1 0 0 5.3 6.3
B 16.0 1.7 21.4 28.1 12.5
C 11.1 3.4 10.7 19.3
B-symptoms (yes %) 12.5 5.1 10.7 21.1 13.3
Involvement of spleen (yes %) 27.8 10.2 42.9 38.6 26.7
Comorbidities (yes %) 27.8 20.3 39.3 29.8 43.7
WHO performance score (%)
0 78.5 84.7 71.4 75.4 75.0
1 19.4 15.3 25.0 21.1 18.8
2 0 0 0 0 6.3
n.a. 2.1 0 3.6 3.5 0
n.a. not available, CLB chlorambucil, HRQoL health-related quality of life
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5.7 per patient, and 127 patients (88.2 %) completed three
or more questionnaires. For 25 patients, we did not have
information during the complete follow-up duration of the
study (see Fig. 1).
Quality of life during total study
Table 2 summarises the results on all instruments used for
the total CLL population and for the three patient groups
that were described before.
Taking into account the total group of CLL patients, the
score on both the EQ-5D and the VAS was lower than the
norm score corrected for age and gender [28]. This also
applies for the subgroups of patients treated with chlo-
rambucil only or with more/other treatments than chlo-
rambucil. Patients who received no active treatment at all,
scored lower on the VAS than the general population, but
not on the utility score of the EQ-5D5.
The patients’ mean score and the mean norm scores per
EORTC QLQ-C30 item/scale are also shown in Table 2. It
identifies the significant differences of p\ 0.05 from the
norm score. Statistically significant differences are, how-
ever, not always clinically meaningful. Meaningful differ-
ences (of more than 10 points [24]) between the norm score
and patients’ score were observed for role functioning and
fatigue in the total group of CLL patients. This was also
applicable to the subgroups of patients treated with chlo-
rambucil only or with more/other treatments than chlo-
rambucil. Other differences were observed for emotional
and cognitive functioning, appetite loss, and sleeping in
patients who only received chlorambucil, for physical and
social functioning, and for dyspnoea in patients who
received more or other treatments than chlorambucil. None
of the significant differences for patients who did not
receive any active treatment were clinically meaningful.
When looking at the total population of CLL patients
that reported ‘‘a little’’, ‘‘quite a bit’’, or ‘‘very much’’
problems on the EORTC QLQ-CLL16 questionnaire, most
patients reported problems on future health concern (62 %
of the questionnaires), feeling to have not enough energy
(50 %), and having night sweats (48 %). For all patient
groups, most problems were reported on future health
concern and night sweats. The subgroup of patients who
were treated with more or different therapies than chlo-
rambucil also reported many problems with respiratory
infections and worries about getting infections. The sub-
group with patients who only received chlorambucil had
the highest (worst) total mean score over all items.
Figure 2 shows that on almost all single items and
scales, the group without any active treatment (watch and
wait approach only) scored best of all patient groups.
Patients who were treated with chlorambucil only scored
worse on HRQoL than patients who were treated with more
or different treatments with regard to emotional function-
ing, cognitive functioning, bruises, uncomfortable stomach,
and apathy (data not shown).
Being currently treated or not did influence the HRQoL.
The 41 patients who filled in questionnaires during treatment
and before/after treatment had a significantly lower utility
score during treatment (data not shown). This pattern was
also observed in the total study sample as presented else-
where when the data were analysed per treatment line [30].
In the total population of CLL patients, scores on the
VAS and EQ-5D5 differed significantly between the cate-
gories of WHO performance status and the presence/ab-
sence of comorbidities (see Supplemental Table 1).
Quality of life during watch and wait phase
and during treatment with chlorambucil
versus general population
HRQoL results during the watch and wait phase are based
on all questionnaires completed before the start of active
treatment. This covers not only patients who did not
receive any active treatment at all, but also the patients who
received a treatment after being in the watch and wait
phase. During the watch and wait phase, HRQoL can be
compromised due to the illness and its related insecurity as
well as by other causes like comorbidities or life events.
The HRQoL during treatment with chlorambucil covers
only those questionnaires which were filled in during active
treatment with chlorambucil.
Enrolled in HRQoL study 
(n=144) 
Not willing to participate 
in HRQoL study 
(n=16) 
Enrolled in main study 
(n=160) 
Lost to follow-up (n=25):  
Completing questionnaire was too exhausting (2),  
Misunderstanding of research method by treating 
specialist (1) 
Deceased (22) 
Analysed (n=144): 
Excluded from analysis (n=0)
Fig. 1 Patient flow chart
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Table 2 Average patient* and norm scores on EQ-5D5, EORTC QLQ-C30 and EORTC QLQ-CLL16 (SD) of the total CLL population, and the
three patient groups
Total group of CLL patients Patient groups
Total group
(n = 144)
Age- and gender-
matched norm score
Patients without any active
treatment (n = 59)
Patients with (watch and wait?)
chlorambucil only (n = 28)
Other patients
(n = 57)
EQ-5D5
Utility 0.85 (0.1) 0.89 (0.0) 0.89 (0.1) 0.82 (0.2)* 0.85 (0.1)
VAS 73.5 (12.9) 83.1 (3.7) 77.6 (12.8) 71.3 (12.0) 70.3 (12.4)
EORTC QLQ-C30—functioning scales
Physical
functioning
79.15 (18.1) 87.18 (5.9) 83.95 (16.2) 75.89 (22.3)* 75.79 (17.8)
Role
functioning
75.44 (22.9) 86.57 (4.2) 81.99 (20.9) 71.30 (23.9) 70.68 (24.8)
Emotional
functioning
85.31 (15.3) 89.89 (2.0) 87.29 (13.4) 77.52 (18.3) 87.09 (16.3)
Cognitive
functioning
84.98 (16.1) 90.81 (2.9) 85.59 (16.3)* 76.50 (18.2) 88.53 (16.6)
Social
functioning
85.61 (18.3) 93.44 (2.4) 90.60 (14.5) 82.76 (22.0)* 81.85 (21.5)
Global health 75.36 (13.8) 77.06 (2.7) 78.68 (13.1) 73.86 (14.7) 72.66 (14.8)*
EORTC QLQ-C30—symptoms
Fatigue 31. 17 (21.0) 17.51 (3.8) 24.96 (21.4) 36.48 (21.1) 34.97 (20.6)
Nausea
vomiting
3.77 (7.7) 2.50 (1.8) 2.31 (5.0) 5.96 (9.9) 4.20 (9.3)
Pain 15.06 (17.9) 17.26 (5.6) 14.48 (18.2) 19.58 (23.0) 13.45 (15.6)
Dyspnoea 18.15 (21.7) 9.30 (3.1) 12.12 (17.9) 19.02 (21.4)* 23.96 (23.0)
Sleeping 22.07 (23.6) 15.18 (4.9) 20.86 (25.0) 28.85 (20.9) 20.00 (25.4)
Appetite loss 8.36 (15.8) 3.48 (1.7) 3.94 (9.6) 16.92 (24.9)* 8.73 (13.9)
Constipation 4.77 (10.5) 5.98 (2.9) 4.41 (9.6) 4.87 (9.9) 5.09 (12.3)
Diarrhoea 4.75 (9.8) 3.96 (0.9) 4.52 (11.2) 5.76 (11.3) 4.50 (7.1)
Financial
difficulties
5.78 (13.8)* 3.33 (1.35) 4.77 (11.5) 5.38 (16.5) 7.03 (20.1)
EORTC QLQ-CLL16
Weight loss 1.15 (0.5) n.a. 1.06 (0.4) 1.34 (0.6) 1.15 (0.6)
Dry mouth 1.38 (0.8) n.a. 1.35 (0.7) 1.61 (0.9) 1.31 (0.7)
Bruises 1.06 (0.5) n.a. 1.05 (0.4) 1.24 (0.7) 0.98 (0.4)
Uncomfortable
stomach
1.27 (0.7) n.a. 1.24 (0.6) 1.49 (0.7) 1.20 (0.6)
Changes in
temperature
1.14 (0.6) n.a. 1.03 (0.4) 1.30 (0.7) 1.17 (0.7)
Night sweats 1.55 (0.9) n.a. 1.42 (0.8) 1.76 (0.9) 1.58 (0.9)
Feeling sick or
unwell
0.78 (0.5) n.a. 0.68 (0.4) 0.99 (0.7) 0.79 (0.5)
Feeling
apathetic
1.41 (0.7) n.a. 1.30 (0.7) 1.71 (0.7) 1.37 (0.7)
Not enough
energy
1.49 (0.8) n.a. 1.36 (0.7) 1.79 (0.8) 1.47 (0.8)
Planning
activities
1.45 (0.8) n.a. 1.29 (0.7) 1.73 (0.9) 1.46 (0.8)
Future health
concern
1.62 (0.8) n.a. 1.50 (0.8) 1.93 (1.0) 1.59 (0.9)
Respiratory
infection
1.42 (0.8) n.a. 1.26 (0.5) 1.42 (0.7) 1.58 (0.9)
Other infection 1.26 (0.6) n.a. 1.19 (0.6) 1.25 (0.6) 1.33 (0.8)
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Both patients in the watch and wait phase and those during
treatment with chlorambucil scored lower on the VAS than
the general population corrected for age and gender distri-
bution (Table 3). The difference in utility was only signifi-
cant for patients treated with chlorambucil (0.81 vs. 0.90).
Supplemental Table 1 shows that scores on the EQ-5D5
were significantly different between the categories of gender,
age at diagnosis, WHO performance status, and the presence/
absence of comorbidities for patients during the watch and
wait phase. During treatment with chlorambucil, none of the
collected patient characteristics influenced the score on the
EQ-5D and VAS significantly (e.g. males vs. females).
When comparing the individual patient scores on the
EORTC QLQ-C30 with the individual age and gender-
adjusted norms scores, the patients’ scores were meaning-
fully different from the norm score on emotional and role
functioning and on sleeping and dyspnoea during treatment
with chlorambucil. Differences were also found for phys-
ical, cognitive, and social functioning and sleeping scales,
but although statistically significant, they were not clini-
cally meaningful. In the watch and wait phase, differences
from the norm score for cognitive, role and physical
functioning, fatigue, and sleeping were statistically signif-
icant, but not clinically meaningful.
With regard to the items of EORTC QLQ-CLL16
module, patients in the watch and wait phase suffered most
from worries about their future health (55 % of the ques-
tionnaires), night sweats (44 %), and having not enough
energy (40 %). Patients during treatment with chlorambu-
cil suffered most from worries about their future health
(78 % of the questionnaires), having not enough energy
(61 %), and infection risk (56 %).
Quality of life during watch and wait phase
versus during treatment with chlorambucil
Patient characteristics of the patients who completed
questionnaires during the watch and wait phase were
comparable with those of the patients who completed
questionnaires during treatment with chlorambucil. Age at
diagnosis was 68.7 versus 67.2 years (p = 0.426), WHO
performance status was 0 in 83.1 versus 82.9 % of the
patients (p = 0.981), and co-morbidity was present in 26.8
versus 37.2 % of the patients (p = 0.195), respectively.
The HRQoL was significantly worse during treatment
with chlorambucil than during the watch and wait phase for
the following outcomes: utility, VAS, emotional function-
ing, social functioning, fatigue, dyspnoea, losing weight,
Fig. 2 Norm scores and patient scores on the EORTC QLQ-C30 and
EQ-5D5. Patient scores on the EORTC QLQ-C30 and EQ-5D5 are
reported for the general population (norm score) [28, 29], the total
CLL group and for the three patient groups separately. The norm
scores present the mean norm score of all CLL patients in our study.
Upper figure results of the functioning scales of the EORTC QLQ-
C30 and the EQ-5D. The higher the score, the higher the quality of
life (range 0–100). Lower figure results of the symptom scales of the
EORTC QLQ-C30 The higher the score, the lower the quality of life
(range 0–100). CLB chlorambucil
Table 2 continued
Total group of CLL patients Patient groups
Total group
(n = 144)
Age- and gender-
matched norm score
Patients without any active
treatment (n = 59)
Patients with (watch and wait?)
chlorambucil only (n = 28)
Other patients
(n = 57)
Repeated use
antibiotics
1.26 (0.7) n.a. 1.10 (0.5) 1.17 (0.5) 1.48 (0.9)
Worries for
infection risk
1.32 (0.7) n.a. 1.10 (0.5) 1.47 (0.8) 1.48 (0.8)
Patient scores were based on an area under the curve analysis
* p\ 0.05,  p\ 0.01,  p\ 0.001 for comparisons with age- and gender-matched norm scores
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changes in temperature, feeling apathetic, lack of energy,
respiratory infections, and risk of infections.
Norm scores were available for the EQ-5D [28] and the
EORTC QLQ-C30 [29]. The mean difference between the
patients’ score and the norm score for that patient was
significantly higher during treatment with chlorambucil
than during the watch and wait phase for the following
scales and items: emotional functioning (p = 0.004),
fatigue (p = 0.021), dyspnoea (p = 0.003), VAS
(p = 0.002), and utility (p = 0.004).
Discussion
This longitudinal observational study showed that the
HRQoL in CLL patients is compromised when compared
with age- and gender-matched norm scores of the general
Table 3 Average patient* and norm scores on EQ-5D5 and EORTC QLQ-C30 (SD) during watch and wait phase and during treatment with
chlorambucil
During watch and
wait
phase (n = 71)
Norm score
watch
and wait phase
p value*** During treatment
with
CLB (n = 42)
Norm score during
treatment with
CLB
p value***
Utility 0.88 (0.1) 0.89 (0.0) 0. 052 0.81 (0.2)** 0.90 (0.0) 0.003
VAS 77.4 (12.4) 82.8 (3.9) 0.000 69.1 (14.5)** 82.7 (3.7) 0.000
Physical functioning 83.2 (15.9) 86.8 (6.1) 0.030 79.0 (18.2) 86.2 (5.3) 0.011
Role functioning 79.8 (21.2) 86.3 (4.4) 0.009 73.3 (22.5) 85.5 (3.5) 0.001
Emotional functioning 86.6 (13.7) 89.7 (2.1) 0.055 78.0 (18.0)** 89.7 (2.1) 0.000
Cognitive functioning 85.2 (16.9) 90.9 (2.9) 0.038 82.6 (19.3) 90.2 (3.0) 0.011
Social functioning 89.9 (15.0) 93.3 (2.5) 0.051 83.5 (20.0)* 92.7 (2.2) 0.004
Global health 78.0 (13.6) 76.9 (2.8) 0.474 72.9 (15.4) 76.4 (2.1) 0.147
Fatigue 25.5 (20.5) 17.7 (4.0) 0.002 22.99 (17.8)* 18.6 (3.1) 0.000
Nausea vomiting 2.9 (5.9) 2.7 (1.9) 0.766 4.49 (15.6) 2.6 (1.8) 0.435
Pain 15.5 (17.6) 17.8 (5.9) 0.254 15.38 (18.3) 18.4 (4.9) 0.279
Dyspnoea 12.1 (18.6) 9.4 (3.2) 0.225 24.28 (26.1)** 9.6 (3.0) 0.001
Sleeping 21.6 (24.6) 15.6 (5.1) 0.032 26.75 (26.3) 16.1 (4.7) 0.012
Appetite loss 5.5 (12.4) 3.6 (1.7) 0.191 9.98 (21.9) 3.7 (1.6) 0.067
Constipation 4.3 (9.4) 6.2 (3.0) 0.085 3.48 (8.6) 6.5 (2.7) 0.025
Diarrhoea 4.4 (10.3) 3.9 (1.0) 0.720 3.62 (8.6) 4.2 (0.8) 0.686
Financial difficulties 5.6 (14.0) 3.4 (1.4) 0.195 5.00 (16.7) 3.5 (1.5) 0.561
Weight loss 1.2 (0.3) n.a. 1.48 (0.3)* n.a.
Dry mouth 1.5 (0.7) n.a. 1.70 (0.7) n.a.
Bruises 1.1 (0.3) n.a. 1.20 (0.3) n.a.
Uncomfortable stomach 1.4 (0.5) n.a. 1.53 (0.6) n.a.
Changes in temperature 1.1 (0.3) n.a. 1.43 (0.3)** n.a.
Night sweats 1.7 (0.7) n.a. 1.95 (0.7) n.a.
Feeling sick or unwell 1.3 (0.4) n.a. 1.45 (0.4) n.a.
Feeling apathetic 1.5 (0.5) n.a. 1.79 (0.6)** n.a.
Not enough energy 1.5 (0.6) n.a. 1.88 (0.6)* n.a.
Planning activities 1.4 (0.6) n.a. 1.74 (0.6) n.a.
Future health concern 1.7 (0.7) n.a. 2.10 (0.7) n.a.
Respiratory infection 1.4 (0.5) n.a. 1.78 (0.5)* n.a.
Other infection 1.3 (0.5) n.a. 1.38 (0.5) n.a.
Repeated use antibiotics 1.3 (0.5) n.a. 1.40 (0.5) n.a.
Worries for infection
risk
1.3 (0.4) n.a. 1.78 (0.4)** n.a.
Patient scores were based on an area under the curve analysis
* A significant difference between the watch and wait phase and treatment with chlorambucil (p value\0.05)
** A significant difference between the watch and wait phase and treatment with chlorambucil (p value\0.01)
*** A value in italics indicates a significant difference between the patient score and norm score (p value\ 0.05)
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population. Patients with CLL differed from the general
population on the VAS and utility score of the EQ-5D5, all
functioning scales of the EORTC QLQ-C30, and the
symptoms of fatigue, dyspnoea, sleeping, appetite loss, and
financial difficulties.
The HRQoL in untreated CLL patients is already com-
promised with regard to physical, role and cognitive func-
tioning, VAS score, fatigue, and sleeping. During treatment
with the most frequently administered therapy in our study
(chlorambucil), patients also had dyspnoea and constipation
and were compromised in their emotional and social func-
tioning. Although we are aware that treatment is initiated
only when there is a treatment indication and clinical benefits
are to be expected, we conclude that starting treatment will
probably further reduce the already slightly compromised
HRQoL during the watch and wait phase—at least tem-
porarily. That applies to the relatively mild agent chloram-
bucil, and that decrease might be even bigger for the more
effective, but also more intensive therapies that are (coming)
available. The expected impact of starting treatment on
HRQoL should therefore be considered in the decision
whether to start treatment or not.
It is remarkable that the HRQoL is already compromised
in untreated patients since in general, treatment is started
when the patients experience B-symptoms or disease pro-
gression. None of the three previous studies that reported
the HRQoL in CLL patients in a non-trial setting, reported
the scale scores of HRQoL in untreated patients. We are
therefore not able to compare our results in untreated
patients with other studies.
When looking at the total group of CLL patients, our
results compare very well with those of Holzner et al. [16],
who found a lower HRQoL in CLL patients compared with
the age- and gender-matched healthy population on 8 of the
15 items/scales of the EORTC QLQ-C30 at baseline. We
came to the same conclusion, but we found more statisti-
cally significant differences (10 of the 15 items/scales)
compared with the general population. However, our
patient scores on the EORTC QLQ-C30 were better than
those reported by Holzner et al. [16]. This is probably due
to the lower age of the patients in our study, and the earlier
disease stage at diagnosis.
A recent article by Pashos et al. [17] reported the
baseline results of the HRQoL study using the Brief Fati-
gue Inventory, EQ-5D, and Functional Assessment of
Cancer Therapy-Leukemia. Our results on the EQ-5D5 are
comparable to those reported by Pashos et al. [17].
In the study by Shanafelt et al. [15], CLL patients scored
only worse than the general population on the emotional
scale of the FACT-G questionnaire. Just like the results of
the study by Shanafelt et al., we found a significant dif-
ference from the norm score on emotional functioning for
the total group of CLL patients, but in contrary to their
study, we found many other differences as well.
Fatigue is one of the most frequently reported symptoms
among patients with CLL. Our study showed that even
untreated patients report significantly more symptoms of
fatigue than the general population, and during or after
treatment the symptoms were worse. It is a common
symptom even many years after diagnosis. More attention
should be given to this symptom during and after treat-
ment, but also during the watch and wait phase. Interven-
tions may help to reduce fatigue, but since the precise
underlying pathophysiology is largely unknown [31], fur-
ther studies are necessary.
Limitations of the study
Since new treatments tend to prolong the overall survival
of CLL patients [32], the quality of life during and after
treatment becomes more important. Although our study
provides insight into the problems that patients with CLL
are likely to have, the relatively small number of patients
did not allow for comparisons between therapies. This
would be very informative for clinicians, but to enable
these comparisons in a real-world setting, many patients
need to be enrolled, given the high number of available
treatments. Due to a low incidence rate of CLL, this would
require a long inclusion period or an international
approach. Changes in management of CLL over time make
it difficult to interpret results of a study with a long
inclusion period, and an international study also carries
difficulties to the interpretation of the results. Fortunately,
the HRQoL results of clinical trials can provide important
information on this issue.
A second limitation of our study was that due to the
observational character of the study, we were dependent on
the health practitioners involved in the study for the timely
administration of questionnaires, specifically the ques-
tionnaire at the start of a new treatment. Despite our efforts
to remind them, they forgot to hand over the questionnaire
to the patients before the start of the treatment in the
majority of the patients who started a new treatment during
our study period. We did not have sufficient information
about the HRQoL at the start of treatment to compare the
HRQoL before and after treatment.
Another limitation is the uncertainty around the utility
scores of the EQ-5D5 instrument. To decrease this uncer-
tainty, we also showed the mean utility over the study period
using two other methods to generate utility values. The first
additional method using a predictive model has been
developed in multiple myeloma and validated in non-
Hodgkin lymphoma patients. The predicted values appeared
to follow a similar pattern to the observed EQ-5D values
[33]. The second additional method used the ‘‘crosswalk’’
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obtained from an international study of the EuroQol group
that administered both the three-level and five-level versions
of the EQ-5D (see their website: www.euroqol.org).
The mean utility score of the midpoint estimation and
the two additional methods for the total CLL group—based
on only those questionnaires without missing values nec-
essary to derive all three estimations—give the following
utility scores: 0.854, 0.847, and 0.844. Since these three
methods give quite similar results, we can conclude that
our calculation is quite reliable.
Since WHO performance status and the presence of
comorbidities influence HRQoL, they are potential con-
founders in our study. We were not able to correct for these
potential confounders due to the heterogeneity in treatment
patterns resulting in too small patient groups to apply for
example propensity score matching. Patients with mea-
surements during the watch and wait phase and those with
measurements during treatment with chlorambucil did,
however, not differ statistically in WHO performance sta-
tus and the presence of comorbidities.
Generalisability
The patient characteristics in our study seem to be rea-
sonably representative for the entire Dutch CLL population
since the distribution of gender and the average age at
diagnosis agree reasonably well with those of the national
registration of CLL and indolent lymphomas (63 vs. 56 %
males and 63 vs. 66 years of age) [34]. The slightly lower
mean age at diagnosis may be caused by the tendency of
haematologists not to bother older patients with the study,
or the higher refusal rate to participate by the older
patients. The distribution of the disease stages, however,
also corresponds with the published distribution in The
Netherlands: Binet stage A: 71 versus 60 %, Binet stage B:
16 versus 30 %, and Binet stage C: 11 versus 10 % [35].
In contrast to most RCTs, we also included patients with
severe co-morbidity. Co-morbidity (severe heart failure,
severe pulmonary disease, severe neurologic disease, severe
metabolic disease, inadequate liver function, inadequate
renal function, or other co-morbidity) was present in 28 % of
the patients. RCTs which aim to study the efficacy of treat-
ments and their influence on HRQoL, often exclude these
patients. The outcome of treatments in daily practice could
therefore differ from the results found in the RCT. We
showed that HRQoL is indeed negatively influenced by
having comorbidities and the WHO stage at diagnosis. In our
study, the patient group ‘‘chlorambucil only’’ had the highest
percentage of patients with co-morbidity. This may explain
the relatively worse HRQoL of the patients in this group
compared with the patients receiving other treatments.
The percentage of patients with comorbidities was even
higher in the group with non-participants. They were also
significantly older at diagnosis than participants. This
might be related to their choice not to participate in the
quality of life study. The percentage of patients willing to
participate in the HRQoL study was, however, very high
(90 %) so that we do not expect that inclusion of these
patients would significantly affect the results.
Since the group of patients with co-morbidity is growing
steadily due to an ageing population and an improved
overall survival, future research should also focus on the
effectiveness of treatments in these patients and the effect
of treatments on their HRQoL.
Conclusion
We concluded that CLL has a profound impact on HRQoL.
The HRQoL in CLL patients is compromised when com-
pared with age- and gender-matched norm scores of the
general population. Patients with CLL differ most from the
general population with regard to the level of role func-
tioning, symptoms of fatigue, concerns about future health,
and lacking energy. For patients in the watch and wait
phase, the impact of their disease was limited, but larger
than generally assumed. In particular with regard to
symptoms of sleeping problems and fatigue, more attention
should be given to these patients. Once treatment was
indicated, HRQoL became considerably compromised.
This applied to all treatments, including chlorambucil,
which is considered to be a mild treatment. The impact of
starting a treatment on the HRQoL should therefore be
weighted in the decision whether to start therapy, espe-
cially since more effective, but also more intensive thera-
pies are becoming available.
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